2023 - Research.com Medicine in Spain Leader Award
Xavier Montalban focuses on Multiple sclerosis, Internal medicine, Surgery, Expanded Disability Status Scale and Magnetic resonance imaging. He works in the field of Multiple sclerosis, namely Clinically isolated syndrome. His Clinically isolated syndrome research includes themes of McDonald criteria and Optic neuritis.
The concepts of his Internal medicine study are interwoven with issues in Gastroenterology, Placebo and Placebo-controlled study. His study looks at the relationship between Surgery and fields such as Fingolimod, as well as how they intersect with chemical problems. His Magnetic resonance imaging research includes elements of Longitudinal study, Predictive value of tests, Cerebrospinal fluid and Treatment response.
His scientific interests lie mostly in Multiple sclerosis, Internal medicine, Immunology, In patient and Clinically isolated syndrome. His study of Expanded Disability Status Scale is a part of Multiple sclerosis. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology, Placebo, Ocrelizumab and Oncology.
His biological study spans a wide range of topics, including Clinical endpoint, Adverse effect and Phases of clinical research. His research on Clinically isolated syndrome often connects related topics like McDonald criteria. His research in Surgery is mostly concerned with Central nervous system disease.
Multiple sclerosis, Internal medicine, In patient, Clinical trial and Ocrelizumab are his primary areas of study. His work deals with themes such as Magnetic resonance imaging, Disease and Intensive care medicine, which intersect with Multiple sclerosis. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology, Placebo and Oncology.
His studies deal with areas such as Observational study and Randomized controlled trial as well as Clinical trial. His study looks at the relationship between Ocrelizumab and topics such as Disability progression, which overlap with Relapse rate. The study incorporates disciplines such as McDonald criteria, Proportional hazards model and Brain size in addition to Clinically isolated syndrome.
Xavier Montalban mostly deals with Multiple sclerosis, Internal medicine, Expanded Disability Status Scale, Clinical trial and In patient. His Multiple sclerosis research focuses on Clinically isolated syndrome in particular. His Clinically isolated syndrome research is multidisciplinary, relying on both McDonald criteria, Proportional hazards model, Cohort study and Cohort.
His Internal medicine research incorporates themes from Gastroenterology, Placebo and Ocrelizumab. His research integrates issues of Patient satisfaction, Clinical endpoint and Physical therapy in his study of Expanded Disability Status Scale. His work in Clinical trial tackles topics such as Randomized controlled trial which are related to areas like Interferon beta-1a, Placebo-controlled study, Myeloid cells, Tyrosine kinase and Bruton's tyrosine kinase.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H Polman;Stephen C Reingold;Brenda Banwell;Michel Clanet.
Annals of Neurology (2011)
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson;Brenda L. Banwell;Frederik Barkhof;Frederik Barkhof;William M. Carroll.
Lancet Neurology (2017)
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Stephen Sawcer;Garrett Hellenthal;Matti Pirinen;Chris C. A. Spencer.
Defining the clinical course of multiple sclerosis: The 2013 revisions
Fred D. Lublin;Stephen C. Reingold;Jeffrey A. Cohen;Gary R. Cutter.
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Jeffrey A. Cohen;Frederik Barkhof;Giancarlo Comi;Hans Peter Hartung.
The New England Journal of Medicine (2010)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Xavier Montalban;Stephen L. Hauser;Ludwig Kappos;Douglas L. Arnold.
The New England Journal of Medicine (2017)
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
Ludwig Kappos;Jack Antel;Giancarlo Comi;Xavier Montalban.
The New England Journal of Medicine (2006)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Stephen L. Hauser;Amit Bar-Or;Giancarlo Comi;Gavin Giovannoni.
The New England Journal of Medicine (2017)
Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity
R. H.S.R. Roxburgh;S. R. Seaman;T. Masterman;A. E. Hensiek.
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
L. Kappos;C.H. Polman;M.S. Freedman;G. Edan.
American Journal of Ophthalmology (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: